Amendment of Section 12 of Articles of Association of Orion Corporation entered in the Trade Register
ORION CORPORATION STOCK EXCHANGE RELEASE 9 APRIL 2014 at 4.45 P.M. EEST
The amendment of Section 12 of the Articles of Association of Orion Corporation in accordance with the decision by the AGM held on 25 March 2014 has been entered in the Trade Register. The current Articles of Association are available on the company's website in the address www.orion.fi/articles-of-association. The decisions of the AGM were published in a Stock Exchange Release of 25 March 2014.
| Timo Lappalainen |
President and CEO
| Olli Huotari |
SVP, Corporate Functions
Olli Huotari, SVP, Corporate Functions
tel. +358 10 426 3054, mobile +358 50 966 3054
Orionintie 1A, FI-02200 Espoo, Finland
Orion is a globally operating Finnish company developing pharmaceuticals and diagnostic tests - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. Pharmaceutical R&D focuses on central nervous system drugs, oncology and critical care drugs, and Easyhaler® pulmonary drugs.
Orion's net sales in 2013 amounted to EUR 1,007 million and the company had about 3,500 employees. Orion's A and B shares are listed on NASDAQ OMX Helsinki.